Skip to main content

Peer Review reports

From: Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study

Original Submission
19 Jan 2024 Submitted Original manuscript
12 Mar 2024 Reviewed Reviewer Report
17 Mar 2024 Reviewed Reviewer Report
29 Mar 2024 Author responded Author comments - Tae-Oh Kim
Resubmission - Version 2
29 Mar 2024 Submitted Manuscript version 2
2 Apr 2024 Author responded Author comments - Tae-Oh Kim
Resubmission - Version 3
2 Apr 2024 Submitted Manuscript version 3
24 Apr 2024 Reviewed Reviewer Report
11 Jun 2024 Reviewed Reviewer Report
18 Jun 2024 Author responded Author comments - Tae-Oh Kim
Resubmission - Version 4
18 Jun 2024 Submitted Manuscript version 4
6 Aug 2024 Reviewed Reviewer Report
10 Aug 2024 Reviewed Reviewer Report - Milan Lukas
29 Aug 2024 Author responded Author comments - Tae-Oh Kim
Resubmission - Version 5
29 Aug 2024 Submitted Manuscript version 5
31 Aug 2024 Author responded Author comments - Tae-Oh Kim
Resubmission - Version 6
31 Aug 2024 Submitted Manuscript version 6
Publishing
4 Sep 2024 Editorially accepted
11 Sep 2024 Article published 10.1186/s12876-024-03403-8

You can find further information about peer review here.

Back to article page